在肺腺癌中，p63的细胞质定位与患者的不良生存情况相关。
Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma.
作者信息
Narahashi T, Niki T, Wang T, Goto A, Matsubara D, Funata N, Fukayama M
机构信息
Department of Human Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo Metropolitan Komagome Hospital, Japan.
出版信息
Histopathology. 2006 Oct;49(4):349-57. doi: 10.1111/j.1365-2559.2006.02507.x.
AIMS
To determine the significance of p63 protein expression in the development and progression of lung adenocarcinoma.
METHODS AND RESULTS
The expression of p63 was immunohistochemically investigated in 92 cases of lung adenocarcinoma with a maximum diameter of 30 mm or less. p63 expression was observed not only in the nuclei (46/92 cases, 50%), but also in the cytoplasm of neoplastic cells (47/92, 51%). Nuclear localization of p63 was correlated with nuclear accumulation of p53 (P=0.0120), whereas the presence of nuclear p63 had no apparent effect on patient survival. Cytoplasmic localization of p63 was found to be correlated with shorter survival periods by univariate and multivariate analyses (P=0.0486 and P=0.0488, respectively) and the relation was independent of clinicopathological factors. Cytoplasmic localization of p63 was further confirmed by immunoblots of the cytoplasmic fraction of HLC-1, a lung adenocarcinoma cell line which predominately expressed DeltaNp63alpha transcript relative to TAp63 transcript by quantitative reverse transcriptase-polymerase chain reaction.
CONCLUSIONS
Cytoplasmic expression of p63 is an adverse prognostic factor in patients with adenocarcinoma of the lung.
目的
确定p63蛋白表达在肺腺癌发生发展中的意义。
方法与结果
采用免疫组织化学方法检测92例最大直径30mm及以下的肺腺癌中p63的表达情况。p63不仅在细胞核中表达（46/92例，50%），也在肿瘤细胞的细胞质中表达（47/92例，51%）。p63的核定位与p53的核聚集相关（P = 0.0120），而核p63的存在对患者生存无明显影响。单因素和多因素分析均发现p63的细胞质定位与较短生存期相关（分别为P = 0.0486和P = 0.0488），且该关系独立于临床病理因素。通过对HLC - 1（一种肺腺癌细胞系）细胞质部分进行免疫印迹进一步证实了p63的细胞质定位，通过定量逆转录 - 聚合酶链反应，该细胞系相对于TAp63转录本主要表达DeltaNp63alpha转录本。
结论
p63的细胞质表达是肺腺癌患者的不良预后因素。
Zotero 插件